

References

I-117

1. Chiavenna S, Jaworski J, Vendrell A. State of the art in anti-cancer mAbs. *J Biomed Sci*, 2017;24(1),15.
2. Moretto R, Cremolini C, Rossini D, et al. Location of primary tumor and benefit from anti-epidermal growth factor receptor monoclonal antibodies in patients with RAS and BRAF wild-type metastatic colorectal cancer. *The Oncologist*. ISSN: 1549-490X, 2016;21 (8), pp. 988-94.
3. Thomson Micromedex DrugDex Compendium®. Panitumumab. 2017.
4. Clinical Pharmacology™ 2021. Tampa FL: Gold Standard, Inc. Panitumumab.
5. Vectibix® (panitumumab) for injection [package insert]. Thousand Oaks, CA.: Amgen. Revised 06/2017.
6. National Comprehensive Cancer Network (NCCN). Panitumumab. NCCN Drugs & Biologics Compendium®. 2021.
7. Kohne CH, Karthaus M, MineurL, et al. Impact of primary tumor location and early tumor shrinkage on outcomes in patients with RAS wild-type metastatic colorectal cancer following first-line FOLFIRI plus panitumumab. *Drugs in R&D*. 2019;19(3):267-275.
8. Pietrantonio F, Fucà G, Rossini D, et al. FOLFOXIRI-bevacizumab or FOLFOX-panitumumab in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer: A propensity score-based analysis. *Oncologist*. 2021;26(4):302-309.
9. Terazawa T, Kato T, Goto M, et al. Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable RAS wild-type colorectal cancer: *Oncologist*. 2021;26(1):17.
10. Rivera F, Karthaus M, Hecht JR, et. al. Final analysis of the randomised PEAK trial: Overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. *Int J Colorectal Dis*. 2017 Aug;32(8):1179-1190.